Özlem Türeci

Cancer drugs might hit the shelves in 2026

Uğur Şahin, one of BioNTech's co-founders, has announced that their company's cancer treatment medicine will hit the shelves as early as 2026.

Şahin, who has been working with his wife Dr. Özlem Türeci for many years on treatments targeting various types of cancers, especially bowel cancer, stated that the drugs they have developed could be on the market in a few years.

Türeci, Şahin recipient of top science award

Özlem Türeci and Uğur Şahin, the co-founders of BioNTech, and Katalin Kario, who also works at the Germany-based, biotechnology firm has been announced as the recipients of Germany's most prestigious medicine prize for their mRNA vaccine work.

They will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2022 on March 14.

Pages